Entero Therapeutics (ENTO) Stock Price, News & Analysis

Company Overview

Entero Therapeutics, Inc. (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.

Entero’s pipeline features multiple lead candidates in varying stages of clinical development. By employing proprietary formulation platforms, the company seeks to optimize oral bioavailability and site‐specific release profiles, enabling precise treatment of localized GI pathology. Entero works closely with academic medical centers, clinical research organizations and patient advocacy groups to advance its programs through regulatory milestones, with the goal of delivering novel treatment options for both adult and pediatric patient populations.

Founded in 2018 and headquartered in Massachusetts, Entero Therapeutics operates with a network of partners and investigators across the United States. The company maintains a lean organizational structure to support focused development and commercialization activities in the GI space. Through disciplined clinical execution and strategic alliances, Entero aims to become a leading provider of specialized therapies that address significant unmet needs in gastrointestinal health.

Key Stats

• Today's Range: $3.92 to $4.24
• 50-Day Range: $2.60 to $6.37
• 52-Week Range: $0.32 to $5.84
• Volume: 77,370 shs
• Average Volume: 2.80 million shs
• Market Capitalization: $6.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Company Calendar

• Last Earnings: 8/14/2025
• Today: 8/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Technology
• Industry: Software
• Sub-Industry: Application Software
• Current Symbol: NASDAQ:ENTO
• Previous Symbol: NASDAQ:ENTO
• CIK: 1604191
• Web: www.enterothera.com
• Phone: 561-589-7020
• Fax: N/A
• Employees: 9
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.06 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -461.02%
• Return on Assets: -14.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.62
• Quick Ratio: 2.62

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.45) per share
• Price / Book: -1.61

Miscellaneous

• Outstanding Shares: 1,588,000
• Free Float: 3,337,000
• Market Cap: $6.27 million
• Optionable: N/A
• Beta: 1.19